Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
World Vitiligo Map
Your guide to the vitiligo community worldwide. Use the selector to filter by patient support groups, specialists, research centers, clinical trial locations, or World Vitiligo Day events.
Directory Information & Disclaimer
This free public directory gathers information from public sources to help connect our global community. Medical professionals and organizations listed are independent and not affiliated with or endorsed by the Vitiligo Research Foundation (VRF), and no fees are accepted for listings.
Because clinics, support groups, and specialists move or update their services over time, some information may occasionally become outdated. As a result, VRF cannot guarantee the complete accuracy or usefulness of listed third-party resources.
Help Us Keep the Map Accurate
Do you need to add a listing, update outdated details, or request a removal? Please reach out to us using the feedback form on our Contact Us page.
Search Map
70 records found for “NCT07431177” · show all
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoCahaba Derm and skin hlth ctr 27, Birmingham, Alabama, 35244, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoFirst OC Dermatology, Fountain Valley, California, 92708, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoEquity Medical, The Bronx, New York, 10455, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Newmarket, Ontario, L3Y 5G8, Canada
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Toronto, Ontario, M3H 5Y8, Canada
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Bordeaux, 33075, France
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Bad Bentheim, 48455, Germany
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Nashik, Maharashtra, 422101, India
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Córdoba, 14004, Spain
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoMedDerm Associates, San Diego, California, 92103, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoClinical Trials Research Institute, Thousand Oaks, California, 91320, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Santiago de Compostela, A Coruna, 15706, Spain
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Barcelona, 08041, Spain
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoGlobal Clinical Professionals, St. Petersburg, Florida, 33714, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoEncore Medical Research, Hollywood, Florida, 33024, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoMiami Derm and Laser Institute, Miami, Florida, 33173, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoDawes Fretzin Clinical Rea Group, Indianapolis, Indiana, 46256, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoRevival Research Institute, Troy, Michigan, 48084, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoSkin Specialists PC, Omaha, Nebraska, 68144, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoInternational Clinical Research Tennessee LCC, Murfreesboro, Tennessee, 37130, United States
1-888-669-6682
FAQOther Questions
- How long does it take to treat vitiligo?
Vitiligo, a condition characterized by the loss of skin pigment, can be unpredictable in both progression and treatment. The time it takes to treat vitiligo varies significantly...
- Why Does the IRS Still Show an Old Revocation for VR Foundation?
IRS Status · A Short FAQ The old entry records the past. Publication 78 shows where VR Foundation stands today. Updated August 2026 · EIN 45-2498489 Tax records are rarely elega...
- What are the best predictors for therapy response in vitiligo?
A fair question. Also a slightly annoying one, because dermatology loves nuance and patients usually want something more like a weather forecast. Still, a few factors do show up...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.